Femasys Inc.

FEMY

Nasdaq; healthcare; SIC 3841, Surgical & Medical Instruments & Apparatus; CIK 0001339005

D/E

on the D/E boundary of 369 graded peers in healthcare

rank 287 of 369; percentile 77.7; sampling error 2.5 points; lower is stronger

A B C D E

D/E, the sloth



Scoreboard	
Profitability	D percentile 68.1
Solvency	C/D percentile 58.5
Growth and financing	C percentile 49.8
Reliability	0.83 AUC filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$12.5M to $120M assets total assets $20.7M
Standard universe	inside revenue above $1M and assets above $10M
Warnings	dilution, short runway not computable: distress, fortress balance sheet
Inputs computable	8 of 14
Graded from	filings received through Mar 31, 2026 218 days before the rescan; latest periodic filing 10-Q received Aug 14, 2026
Last close	$1.39 2026-11-03; market equity $11.6M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 31, 2026

We are a leading biomedical innovator, addressing significant unmet needs in women's health worldwide, with a broad patent-protected portfolio of disruptive, accessible, in-office therapeutic and diagnostic products. The Company is a U.S. manufacturer that has received global regulatory approvals for its product portfolio, which is currently being commercialized in the U.S. and key international markets. FemaSeed® Intratubal Insemination, a groundbreaking first-step infertility treatment delivering sperm directly to the site of conception, is U.S. FDA-cleared and approved in Europe, United Kingdom (UK), Canada, Israel, Australia and New Zealand.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 68.1						
Gross profitability	6.9%	32.4%		80.8	365	2025-12-31
Return on invested capital	not computable	9.3%				

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

one or more required annual facts are missing						
Accruals ratio	0.4%	(6.6%)	82.5	803	2025-12-31	
Gross margin stability, five years	2.3 pts	2.8 pts	41.1	242	2025-12-31	
Solvency, sleeve percentile 58.5						
Twelve-month failure probability	not computable	0.08%				
latest liabilities, cash plus short-term investments, book equity, and shares are required						
Altman Z double-prime	(24.17)	(0.35)	76.8	747	2025-12-31	
Net debt to EBITDA	not computable	1.82x				
one or more required annual facts are missing						
Interest coverage	not computable	(4.51x)				
latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31						
Current ratio	4.53x	2.92x	40.3	828	2025-12-31	
Growth and financing, sleeve percentile 49.8						
Revenue growth, three-year compound	23.9%	10.1%	27.7	412	2025-12-31	
Free cash flow growth, three-year compound	not computable	10.9%				
current FCF must be positive and base FCF must exceed $100,000						
Reinvestment rate	not computable	37.1%				
pretax income must exceed the validity floor and imply a 0%-100% tax rate						
Asset growth, three years	7.0%	2.2%	36.6	697	2025-12-31	
Net share issuance, one year	122.4%	2.5%	85.1	632	2026-03-30	

Warnings

2 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 122.4%
Short runway	cash runway is 1.0 months

Among 369 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
282	Vivos Therapeutics, Inc. (VVOS)	76.4	D	dilution, short runway, late filer
283	Baxter International Inc. (BAX)	76.6	D	
284	Tilray Brands, Inc. (TLRY)	76.9	D	fortress balance sheet
285	Quest Diagnostics Inc. (DGX)	77.2	D	
286	biote Corp. (BTMD)	77.4	D	
287	Femasys Inc. (FEMY)	77.7	D/E	dilution, short runway
288	Protalix BioTherapeutics, Inc. (PLX)	78.0	D/E	
289	Milestone Scientific Inc. (MLSS)	78.3	D/E	late filer
290	Gilead Sciences, Inc. (GILD)	78.5	D/E	
291	Whitehawk Therapeutics, Inc. (WHWK)	78.8	D/E	
292	Ironwood Pharmaceuticals Inc. (IRWD)	79.1	D/E	late filer, fortress balance sheet

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

What the price implies

at the 2026-11-03 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(83.0%)	(2.2%)	4
Distance from 52-week high	(93.3%)	(29.8%)	3
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	(163.9%)	(0.9%)	4
Book value to price	0.34	0.28	57
Sales to price	0.20	0.30	39
Composite equity issuance, five years	not computable	20.5%	
Relative strength against the sector, log excess return	(1.94)	(0.19)	4

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	fail
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$1.4M
Operating cash flow, four quarters	-$17.7M
Months of runway	1.0
Days since last periodic filing	82 (10-Q received Aug 14, 2026)
Median daily dollar volume, 63 sessions	$217,346

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$2.3M	2025-12-31	2026-03-31	10-K	26-012375
2	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$872,400	2025-12-31	2026-03-31	10-K	26-012375
3	assets	us-gaap:Assets	$20.7M	2025-12-31	2026-03-31	10-K	26-012375
4	net income	us-gaap:NetIncomeLoss	-$18.6M	2025-12-31	2026-03-31	10-K	26-012375
5	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$18.7M	2025-12-31	2026-03-31	10-K	26-012375
6	assets	us-gaap:Assets	$12.4M	2024-12-31	2026-03-31	10-K	26-012375
7	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$1.6M	2024-12-31	2026-03-31	10-K	26-012375
8	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$544,903	2024-12-31	2026-03-31	10-K	26-012375
9	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$1.1M	2023-12-31	2025-03-27	10-K	25-010598
10	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$380,069	2023-12-31	2025-03-27	10-K	25-010598
11	gross profit	us-gaap:GrossProfit	$764,280	2022-12-31	2023-07-24	10-K/A	23-035663
12	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$1.2M	2022-12-31	2024-03-28	10-K	24-016230
13	gross profit	us-gaap:GrossProfit	$809,305	2021-12-31	2023-07-24	10-K/A	23-035663
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$1.2M	2021-12-31	2023-07-24	10-K/A	23-035663
15	current assets	us-gaap:AssetsCurrent	$16.5M	2025-12-31	2026-03-31	10-K	26-012375
16	current liabilities	us-gaap:LiabilitiesCurrent	$3.6M	2025-12-31	2026-03-31	10-K	26-012375
17	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$145.8M	2025-12-31	2026-03-31	10-K	26-012375
18	operating income	us-gaap:OperatingIncomeLoss	-$17.6M	2025-12-31	2026-03-31	10-K	26-012375

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

19	book equity	us-gaap:StockholdersEquity	$5.9M	2025-12-31	2026-03-31	10-K	26-012375
20	liabilities	us-gaap:Liabilities	$14.9M	2025-12-31	2026-03-31	10-K	26-012375
21	operating income	us-gaap:OperatingIncomeLoss	-$14.5M	2023-12-31	2025-03-27	10-K	25-010598
22	interest expense	us-gaap:InterestExpense	$165,390	2023-12-31	2024-03-28	10-K	24-016230
23	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$525,007	2025-12-31	2026-03-31	10-K	26-012375
24	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$19.4M	2024-12-31	2026-03-31	10-K	26-012375
25	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$761,706	2024-12-31	2026-03-31	10-K	26-012375
26	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$11.3M	2023-12-31	2025-03-27	10-K	25-010598
27	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$143,917	2023-12-31	2025-03-27	10-K	25-010598
28	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$10.7M	2022-12-31	2024-03-28	10-K	24-016230
29	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$407,475	2022-12-31	2024-03-28	10-K	24-016230
30	depreciation amortization	us-gaap:Depreciation	$295,859	2025-12-31	2026-03-31	10-K	26-012375
31	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$18.6M	2025-12-31	2026-03-31	10-K	26-012375
32	income tax	us-gaap:IncomeTaxExpenseBenefit	$1,297	2025-12-31	2026-03-31	10-K	26-012375
33	current assets	us-gaap:AssetsCurrent	$8.0M	2024-12-31	2026-03-31	10-K	26-012375
34	current liabilities	us-gaap:LiabilitiesCurrent	$8.6M	2024-12-31	2026-03-31	10-K	26-012375
35	assets	us-gaap:Assets	$27.8M	2023-12-31	2025-03-27	10-K	25-010598
36	assets	us-gaap:Assets	$16.9M	2022-12-31	2024-03-28	10-K	24-016230
37	shares outstanding	dei:EntityCommonStockSharesOutstanding	60,390,686	2026-03-30	2026-03-31	10-K	26-012375
38	shares outstanding	dei:EntityCommonStockSharesOutstanding	27,149,971	2025-03-26	2025-03-27	10-K	25-010598

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.